327 Drug Products to Enter China's 7th Round of Volume-based Procurement (VBP)

by Grace Wang Jul 15, 2022

On July 13, the National Joint Drug Procurement Office announced the preliminary result for the bid of the 7th round of volume-based procurement (VBP). 327 products (60 types drugs if differentiated by the type and content ratio of active ingredient) owned by 217 companies won the bid in the preliminary stage.1

The bid-winning products cover 31 disease categories, including common and/or chronic diseases such as hypertension, diabetes, gastrointestinal disorders and severe diseases of lung/liver/kidney/colon cancer.

The bid-winning products' prices reduced by 48% on average. In terms of kidney cancer drugs, the average price of Lenvatinib Mesilate Capsules was cut by 83.33% from 108 yuan/capsule to 18 yuan/capsule. Among drugs for treating high-blood pressure, Nifedipine Controlled-release Tablets' average price dropped by 58% and Metoprolol Succinate Sustained-Release Tablets' by 53%.

In the 327 products, 6 are from international pharm companies and their VBP prices are listed below.

Drug Product

Specification

Company

VBP Price

Oseltamivir Phosphate Capsules

75mg*10 capsules per blister pack in each box

Hetero Labs Limited

16.50 yuan/box

Iopamidol Injection

100ml: 37g(I)*10 bottles in each box

Shanghai Bracco Sine Pharmaceutical Industry Co., Ltd.

1,192.79   yuan/box

Ebastine Tablets

10mg*10 tablets per blister pack in each box

Almirall, S.A. (Industrias Farmaceuticas Almirall, S.A.)

3.49 yuan/box

Ezetimibe Tablets

10mg*30 tablets in each box

Sandoz Inc. (Lek Pharmaceuticals d.d.)

38.89   yuan/box

Micafungin Sodium for Injection

50mg*1 bottle in each box

Astellas Pharma Europe B.V. (Astellas Pharma Tech Co., Ltd. Takaoka Plant)

86.81 yuan/box

Tigecycline for Injection

50mg*10 phials in each box

Pfizer Europe MA EEIG (Wyeth Lederle

S.r.l.)

415.90   yuan/box

Since 2018, China National Healthcare Security Administration (NHSA) has organized 7 rounds of VBPs which cover 294 types of drugs. According to the estimation based on pre-VBP prices, drugs in the VBPs account for 35% of the chemical drugs and biological products procured by public medical institutions.

UpdateChina Unveils the Final Tender Result of the 7th Volume-based Procurement (VBP) for Drugs

Articles on Previous VBPs:

Grace Wang
ChemLinked Regulatory Analyst
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2022 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com